Cell Reset: siRNA for Transcription Factors
TRANSCRIPTIONAL DAMAGE
Diseases that reduce human lifespan are linked to transcriptional-level cellular damage.
Junevity identifies genes that regulate cellular damage and health—transcription factors—and restores their expression to healthy levels.
BREAKTHROUGH SCIENCE
Junevity’s founders spent nearly a decade creating a platform to identify transcription factors that can restore aged cells to health using human transcriptomics, AI/ML and siRNA.
JUNEVITY RESET DISCOVERY PLATFORM
The RESET Platform is the first to use large-scale human data, AI and siRNA to unlock therapeutics targeting transcription factors.
This approach offers a path to safe, effective therapeutics to reset the health of our tissues, one at a time.
THERAPEUTICS DEVELOPMENT
Junevity is pioneering first-in-class siRNA therapeutics to treat diseases impacting billions of people worldwide.
The first programs are in Type 2 Diabetes, Obesity, CNS, Osteoarthritis and Sarcopenia.
We imagine a world with longer, healthier lives for all.